Trade ORIC Pharmaceuticals, Inc. - ORIC CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.07 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 10.02 |
| Open | 9.96 |
| 1-Year Change | 20.73% |
| Day's Range | 9.54 - 10 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jan 17, 2025 | 9.54 | -0.44 | -4.41% | 9.98 | 10.13 | 9.54 |
| Jan 16, 2025 | 10.02 | -0.83 | -7.65% | 10.85 | 11.09 | 9.92 |
| Jan 15, 2025 | 10.83 | 0.85 | 8.52% | 9.98 | 11.05 | 9.54 |
| Jan 14, 2025 | 9.87 | 1.02 | 11.53% | 8.85 | 10.00 | 8.84 |
| Jan 13, 2025 | 8.56 | 0.18 | 2.15% | 8.38 | 8.68 | 7.89 |
| Jan 10, 2025 | 7.93 | -0.21 | -2.58% | 8.14 | 8.16 | 7.83 |
| Jan 8, 2025 | 8.47 | -0.34 | -3.86% | 8.81 | 8.96 | 8.28 |
| Jan 7, 2025 | 9.17 | 0.88 | 10.62% | 8.29 | 9.41 | 8.13 |
| Jan 6, 2025 | 8.29 | -0.19 | -2.24% | 8.48 | 8.60 | 8.13 |
| Jan 3, 2025 | 8.50 | 0.25 | 3.03% | 8.25 | 8.58 | 8.24 |
| Jan 2, 2025 | 8.23 | 0.07 | 0.86% | 8.16 | 8.26 | 8.01 |
| Dec 31, 2024 | 8.03 | 0.02 | 0.25% | 8.01 | 8.15 | 7.85 |
| Dec 30, 2024 | 8.10 | 0.12 | 1.50% | 7.98 | 8.24 | 7.84 |
| Dec 27, 2024 | 8.20 | 0.03 | 0.37% | 8.17 | 8.30 | 7.93 |
| Dec 26, 2024 | 8.28 | 0.20 | 2.48% | 8.08 | 8.39 | 8.01 |
| Dec 24, 2024 | 8.12 | -0.14 | -1.69% | 8.26 | 8.26 | 7.96 |
| Dec 23, 2024 | 8.31 | 0.12 | 1.47% | 8.19 | 8.47 | 8.11 |
| Dec 20, 2024 | 8.19 | 0.82 | 11.13% | 7.37 | 8.21 | 7.35 |
| Dec 19, 2024 | 7.66 | -0.01 | -0.13% | 7.67 | 7.86 | 7.47 |
| Dec 18, 2024 | 7.64 | -0.52 | -6.37% | 8.16 | 8.35 | 7.37 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
ORIC Pharmaceuticals, Inc. Company profile
About ORIC Pharmaceuticals Inc
ORIC Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by overcoming resistance in cancer. The Company is focused on developing a diverse pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its experience within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its product candidates include ORIC-101, ORIC-533, ORIC-944 and ORIC-114. The Company’s ORIC-101 is a potent and selective small-molecule antagonist of the glucocorticoid receptor (GR), which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. The Company’s second product candidate, ORIC-533, is an orally bioavailable, small-molecule inhibitor of CD73, a key node in the adenosine pathway in resistance to chemotherapy-and immunotherapy-based treatment regimens. Its ORIC-944, is being developed for prostate cancer and breast cancer.
Financial summary
BRIEF: For the nine months ended 30 September 2021, ORIC Pharmaceuticals Inc revenues was not reported. Net loss increased 23% to $55.9M. Higher net loss reflects Research and development - Balancing val increase from $15.4M to $36.5M (expense), General and administrative - Balancing increase of 93% to $10.2M (expense), Stock-based Compensation in SGA increase from $1.9M to $5.8M (expense).
| Industry: | Bio Therapeutic Drugs |
240 E. Grand Ave
2nd Floor
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
News
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
12:40, 31 December 2024
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com